Contortrostatin, a dimeric disintegrin from Agkistrodon contortrix contortrix, inhibits breast cancer progression

Area of Science:

• Biochemistry
• Oncology
• Pharmacology

Background:

• Snake venom contains bioactive peptides with therapeutic potential.
• Disintegrins are a class of snake venom proteins known to inhibit integrin function.
• Breast cancer progression involves cell adhesion, invasion, and angiogenesis.

Purpose of the Study:

• To investigate the effect of contortrostatin, a snake venom disintegrin, on breast cancer progression.
• To identify the molecular targets and mechanisms of contortrostatin's action.
• To evaluate contortrostatin's efficacy in inhibiting tumor growth and metastasis in vivo.

Main Methods:

• In vitro studies on cell adhesion and invasion using breast cancer cells (MDA-MB-435).
• Orthotopic xenograft nude mouse model to assess tumor growth and metastasis.
• Immunohistochemical analysis to evaluate angiogenesis.
• Identification of integrin binding sites using cell adhesion assays.

Main Results:

• Contortrostatin inhibited breast cancer cell adhesion to fibronectin and vitronectin, and prevented invasion.
• Daily injection of contortrostatin significantly reduced tumor growth (74%) and pulmonary metastasis (68% macro-, 62.4% micro-) in mice.
• Contortrostatin did not affect cancer cell proliferation or viability in vitro.
• Contortrostatin inhibited tumor-induced angiogenesis.
• Integrin alpha(v)beta3 was identified as a key binding site for contortrostatin.

Conclusions:

• Contortrostatin effectively inhibits breast cancer progression, including tumor growth and metastasis, by targeting integrins, particularly alpha(v)beta3.
• Contortrostatin's mechanism involves blocking integrin-mediated cell adhesion, invasion, and angiogenesis.
• Contortrostatin represents a potential therapeutic agent for breast cancer treatment.